Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) has set its sights on achieving non-GAAP operating income profitability by 2025.
The company has provided its full-year 2025 combined net product revenue forecast for its key products: ONPATTRO, AMVUTTRA (both PN & CM), GIVLAARI, and OXLUMO. This guidance is set between $2.050 billion and $2.250 billion, marking an anticipated growth of 31% over 2024, based on the midpoint of the projected range.
For the fourth quarter, preliminary global net product revenues stood at approximately $56 million for ONPATTRO and $287 million for AMVUTTRA. Similarly, GIVLAARI and OXLUMO generated preliminary revenues of around $65 million and $44 million, respectively.
